The healthcare giant posted adjusted earnings per share of $2.82, exceeding analysts' predictions by $0.10, and a revenue of $22.45 billion, also topping the consensus estimate of $22.34 billion.
Johnson & Johnson's financial results showed a 10.2% increase in adjusted EPS despite a 5.9% decrease in reported EPS due to one-time special charges. Looking ahead, Johnson & Johnson has raised its full-year 2024 operational sales guidance, reflecting the acquisition of Shockwave Medical and updates to its adjusted operational EPS guidance to account for improved performance and recent strategic acquisitions.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: